Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response - Report - MDSpire

Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response

  • By

  • Marcela Vela-Amieva

  • Isabel Ibarra-González

  • Raúl Calzada León

  • María de la Luz Ruiz-Reyes

  • María Eugenia Constantini

  • Sara Guillén-López

  • Lizbeth López-Mejía

  • Michelle Citlalli Luna-Nequiz

  • Rosa Itzel Carrillo-Nieto

  • Cynthia Fernández-Lainez

  • July 1, 2026

  • 0 min

Share

Clinical Report: Metabolomic and Inflammatory Profiles in Congenital Hypothyroidism

Overview

This study investigates the metabolomic and inflammatory changes in pediatric patients with congenital hypothyroidism undergoing levothyroxine treatment. Significant alterations in sphingolipid metabolism were observed, alongside persistent elevation of inflammatory markers.

Background

Congenital hypothyroidism (CH) is a critical endocrine disorder that can lead to severe neurodevelopmental impairments if untreated. Early and effective levothyroxine (LT4) therapy is essential for preventing these outcomes. However, traditional monitoring methods may not fully capture the metabolic and inflammatory changes that occur during treatment.

Data Highlights

Metabolite ChangesPre TxPost Tx
CeramidesElevatedReduced
HexosylceramidesElevatedReduced
SphingomyelinsReducedIncreased

Key Findings

  • Nine metabolites distinguished Pre Tx and Post Tx samples in CH patients.
  • Reduced levels of ceramides and hexosylceramides were noted post-treatment.
  • Increased sphingomyelin levels were observed after LT4 therapy.
  • Circulating TNF-α and IL-10 remained elevated throughout the study period, with no statistically significant differences in inflammatory markers found between time points.
  • A modest increase in length-for-age Z-score was noted in the Post Tx group.

Clinical Implications

Monitoring sphingolipid levels could enhance understanding of treatment responses beyond traditional thyroid function tests.

Conclusion

The study highlights the importance of metabolomic and inflammatory assessments in understanding the biochemical response to LT4 therapy in congenital hypothyroidism.

Related Resources & Content

  1. American Academy of Pediatrics, Pediatrics, 2022 -- Congenital Hypothyroidism: Screening and Management
  2. Frontiers in Endocrinology, 2026 -- Treatment of mild subclinical hypothyroidism and its impact on lipid metabolism
  3. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Longitudinal Analysis of Congenital Hypothyroidism With Gland In Situ and the Requirement for L-Thyroxine Treatment Upon Follow-Up Assessment
  4. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Impact of Prior Psychiatric Conditions on Liothyronine Administration in Hypothyroidism: A Nationwide Cohort Analysis from Sweden
  5. Frontiers, 2026 -- Metabolomic and Inflammatory Signatures in Congenital Hypothyroidism: A Longitudinal Analysis of Levothyroxine Response
  6. The Journal of Clinical Endocrinology & Metabolism — Exploring Digenic Inheritance Patterns in Congenital Hypothyroidism Linked to Thyroid Dysgenesis: Findings from the HYPOTYGEN Translational Study
  7. Congenital Hypothyroidism: Screening and Management | Pediatrics | American Academy of Pediatrics
  8. Frontiers | Metabolomic and Inflammatory Signatures in Congenital Hypothyroidism: A Longitudinal Analysis of Levothyroxine Response

Original Source(s)

Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response

  • by Marcela Vela-Amieva, Isabel Ibarra-González, Raúl Calzada León, María de la Luz Ruiz-Reyes, María Eugenia Constantini, Sara Guillén-López, Lizbeth López-Mejía, Michelle Citlalli Luna-Nequiz, Rosa Itzel Carrillo-Nieto, Cynthia Fernández-Lainez

  • July 1, 2026

Related Content

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

Adrenal tumor microenvironment: hormone–immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities